Vita 34 Confirms Earnings Increase of 28.6 Percent per Share 2014

Vita 34 AG / Key word(s): Final Results

2015-03-26 / 07:33

Vita 34 Confirms Earnings Increase of 28.6 Percent per Share 2014

Leipzig March 26, 2015 – Vita 34 AG (WKN A0BL84) continued its 2014 growth trend and published its complete 2014 annual report today. Thanks to the ongoing positive profit situation, the Management Board and Supervisory Board have proposed for the first time to the Annual General Meeting the payment of a dividend. A dividend in the amount of EUR 0.15 per share is to be paid for fiscal year 2014.

The period result improved by 25.6 percent in fiscal year 2014 compared to the year before. The earnings per share increased by 28.6 percent to EUR 0.36 (2013: EUR 0.28). This positive development is reflected in the key group figures:

– Total operating revenue EUR 15.2 million (2013: EUR 14.8 million) +2.7%

– Sales revenue EUR 13.8 million (2013: EUR 13.6 million) +1.7%

– EBITDA EUR 2.8 million (2013: EUR 2.7 million) +4.4%

– EBIT EUR 1.7 million (2013: EUR 1.5 million) +15.0%

– Period result EUR 1.0 million (2013: EUR 0.8 million) +25.6%

The profitability can be attributed, in particular, to an optimized cost structure. In addition, income from a positive court decision in favor of Vita 34 was posted.

Within the scope of the growth strategy, Vita 34 has extended its presence in Europe and advanced its activities in South East Asia In the reporting period. Consequently the penetration and opening of new markets will continue in the new fiscal year 2015.

Vita 34 intends to expand the value chain with new products for pharmaceutical production and, thus, persistently strengthen its market position as a specialist in the cryo-preservation of biological materials. In fiscal year 2014 the VitaPlusCord product was established in the German-speaking region, as well as via local sales partners in the European market. Stem cell deposits from umbilical cord tissue from several countries are already being stored in Leipzig.

Vita 34 has further identified additional possibilities for the isolation of stem cells from other tissues in the course of its research and development activities. In particular, the research project involving the cryo-preservation of stem cells from fatty tissue started in fiscal year 2014 will be consistently pursued in the current fiscal year.

In light of the strong market position, with a solid equity ratio of some 60 percent and cash of EUR 3.7 million, Dr. André Gerth is looking forward to future corporate development with confidence: “As the undisputed market leader in the German-speaking countries, we are well equipped for the future. We will use our increased profitability in order to achieve significantly more aggressive revenue and profit growth within the context of a Buy and Build strategy in the medium term. The three core of our growth strategy – market penetration and the opening of new markets, the development of the product ranges, as well as the expansion of research activities – form the foundation for this,” says Dr. André Gerth.

Due to the ongoing tense economic situation in Europe and the necessary expenditures for implementing its corporate strategy, Vita 34 expects total operating revenues and an operating result (EBITDA) at the 2014 level for the current fiscal year. Vita 34 expects that EBIT, EBITDA margin and the number of newly stored stem cell deposits will also be at last year’s levels. In addition, an equity ratio of some 60 percent has been set as a goal.

The complete Annual Report 2014 is available for download now on the website at in the “Investor Relations” section.

Company Profile

Vita 34 was founded in 1997 as the first private umbilical cord blood bank in Europe and, as a complete provider, offers collection logistics, preparation and storage of umbilical cord blood and cord tissue. The basis for its successful work is an outstanding position in the technological segment of cryo-preservation. Here, cells and tissue are preserved alive at some -190ºC for long periods of time, and can be used if needed in the context of medical treatment. More than 123,000 families are already taking advantage of this offering and have provided for their children with a stem cell deposit at Vita 34.


2015-03-26 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at and

337683  2015-03-26